- Home
- HOG vs ACAD Comparison
HOG vs ACAD Comparison
Compare HOG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOG
- ACAD
- Stock Information
- Founded
- HOG 1903
- ACAD 1993
- Country
- HOG United States
- ACAD United States
- Employees
- HOG N/A
- ACAD N/A
- Industry
- HOG Motor Vehicles
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- HOG Consumer Discretionary
- ACAD Health Care
- Exchange
- HOG Nasdaq
- ACAD Nasdaq
- Market Cap
- HOG 3.3B
- ACAD 3.9B
- IPO Year
- HOG N/A
- ACAD 2004
- Fundamental
- Price
- HOG $24.12
- ACAD $23.83
- Analyst Decision
- HOG Buy
- ACAD Buy
- Analyst Count
- HOG 7
- ACAD 21
- Target Price
- HOG $28.00
- ACAD $29.00
- AVG Volume (30 Days)
- HOG 2.3M
- ACAD 1.6M
- Earning Date
- HOG 11-04-2025
- ACAD 11-05-2025
- Dividend Yield
- HOG 3.00%
- ACAD N/A
- EPS Growth
- HOG N/A
- ACAD 98.53
- EPS
- HOG 4.04
- ACAD 1.54
- Revenue
- HOG $4,664,627,000.00
- ACAD $1,047,118,000.00
- Revenue This Year
- HOG N/A
- ACAD $14.12
- Revenue Next Year
- HOG $3.94
- ACAD $11.80
- P/E Ratio
- HOG $5.94
- ACAD $15.51
- Revenue Growth
- HOG N/A
- ACAD 12.69
- 52 Week Low
- HOG $20.45
- ACAD $13.40
- 52 Week High
- HOG $35.21
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- HOG 41.35
- ACAD 57.82
- Support Level
- HOG $22.17
- ACAD $22.81
- Resistance Level
- HOG $24.08
- ACAD $23.98
- Average True Range (ATR)
- HOG 0.89
- ACAD 1.12
- MACD
- HOG -0.13
- ACAD 0.05
- Stochastic Oscillator
- HOG 52.39
- ACAD 82.19
About HOG Harley-Davidson Inc.
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring segments, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 37% of the heavyweight domestic market in 2024.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.